二甲双胍.pdf

News Release

November 14, 2011

Merck Serono to Mark World Diabetes Merck Serono is a division of Merck.
9 Chemin des Mines
1202 Genève
Suisse
Media relations
Tel: +41 22 414 36 00News Release
proud that metformin is recommended by the IDF as the first-line treatment of choice
for type 2 diabetes 2, and that Merck Serono’s Glucophage® continues to be the
worldwide leading brand in volumes of metformin 1”, she added.

Merck Serono has a long history in the treatment of Type 2 diabetes, the most common
form of diabetes worldwide accounting for at least 90% of all cases of diabetes 5. The
company developed metformin in 1957, and started its first commercialization under
the brand name Glucophage® in France. Since 2005, the IDF has recommended
metformin as the treatment of choice for first-line therapy in its first ever evidence-
based Global guidelines for the management of type 2 diabetes 2. To respond to
patients’ individual needs, the company went on developing new formulations and
presentations of metformin including Glucophage® XR, an extended release
formulation, Glucophage® Powder Formulation in Sachets, and Glucovance®
(metformin and glibenclamide), a fixed-dose combination thera